Live feed08:00:00·144dNEWSReleasevia QuantisnowEnsysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation OpioidByQuantisnow·Wall Street's wire, on your screen.ENSC· Ensysce Biosciences Inc.Health Care
